Navigation Links
Drug Royalty Corporation Changes Its Name to DRI Capital
Date:10/10/2007

TORONTO, Oct. 10 /PRNewswire/ -- DRI Capital announced that after close to 15 years, it is retiring the name Drug Royalty Corporation and will now officially be known as DRI Capital.

DRI Capital is a privately held investment management company, focused on the healthcare industry, with over US$1 billion under management. DRI Capital currently manages two funds: the Royalty Monetization Fund and the Structured Finance Fund.

Its Royalty Monetization Fund acquires existing royalty streams at competitive rates from companies, institutions and inventors. DRI Capital is a leader in monetizing royalties, having acquired over US$850 million in royalty-based cash flows on commercialized products. In 2007 alone, DRI Capital has deployed about US$450 million with royalty acquisitions on products such as Enbrel, Flumist, Preotact and PEG-INTRON.

Its Structured Finance Fund will soon close with approximately US$300 million in committed capital. This Fund provides predominantly non-dilutive financing for product acquisitions and launches, M & A, in-licensing, sales force expansion and general working capital purposes to companies within the healthcare industry. The Fund invests in cash flow monetization structures which can include debt and equity components, custom tailored to fit the needs of clients.


'/>"/>
SOURCE DRI Capital
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Trouble-shooting: Misincorporation or low fidelity
2. Roche Diagnostics Corporation
3. Roche Diagnostics Corporation
4. Promega Corporation: Wisconsins quiet innovator
5. Giuliani will keynote RedPrairie Corporations user conference
6. Madison Development Corporation makes loans to three area companies
7. Corporations and blogging
8. Metavante acquires Florida banking corporation
9. TriMas Corporations Cequent Group Acquires Chem-Chrome, Inc.
10. Detect Single Nucleotide Sequence Changes with Mx4000 Molecular Beacon Allelic Discrimination Kits
11. The measurement of DNA condensation and mitochondrial changes during apoptosis and necrosis in cell based assays
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... NEW YORK , Oct. 22, 2014 ... Diabetes Federation, approximately 400 million people worldwide are living ... 552 million people by 2030.  The global market for ... In 2012 approximately 330,000 people worldwide died from pancreatic ... of death due to cancer in the ...
(Date:10/22/2014)... HONG KONG , Oct. 22, 2014  aTyr ... today that rare disease expert John C. McKew ... Dr. McKew brings more than two decades of expertise ... National Institutes of Health, Wyeth Research and Genetics Institute, ... lead aTyr,s efforts to expand and translate its novel ...
(Date:10/20/2014)... Oct. 20, 2014 Mapp Biopharmaceutical,s valiant ... antibody therapeutic to fight the Ebola outbreak will ... time-consuming the production of pharmaceuticals can be, according ... said that while some may be taken aback ... those with industry knowledge are well aware of ...
(Date:10/20/2014)... Oct. 20, 2014 Asterias Biotherapeutics, Inc. ... has signed a Notice of Grant Award (NGA) ... effective October 1, 2014.  The NGA provides for ... the release of additional grant funds pursuant to ... for clinical development of Asterias, product, AST-OPC1. The ...
Breaking Biology Technology:Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4
... BioLife Solutions, Inc.,(OTC Bulletin Board: BLFS), ... hypothermic storage and cryopreservation media products for ... of its new quarterly,newsletter BioPreservation Today, a ... and processes, to maximize the yield and,function ...
... Md., Jan. 26 MaxCyte, Inc., the pioneer ... the presentation of the MaxCyte(R) STX(TM) Scalable Transfection ... Session, a joint program of the Association for ... Group (LRIG). The Rapid Fire Innovation Session showcases ...
... as subcontractor to Battelle for submission of proposals ... 26 Corgenix Medical Corporation (OTC Bulletin Board: ... test kits, has announced a collaboration with Battelle, ... whose business focus includes national security. Under the ...
Cached Biology Technology:BioLife Solutions Launches BioPreservation Today(R) Industry Newsletter 2BioLife Solutions Launches BioPreservation Today(R) Industry Newsletter 3The MaxCyte(R) STX(TM) Scalable Transfection System to be Presented at the Rapid Fire Innovation Session at LabAutomation2009 2Corgenix Signs Collaboration With Battelle 2Corgenix Signs Collaboration With Battelle 3
(Date:10/19/2014)... electricity access in India over the last 30 ... carbon emissions growth during that time, according to ... Nature Climate Change ., "Energy access is fundamental ... of life, including education, communication, and health," says ... , While increased energy access is widely agreed ...
(Date:10/18/2014)... sample of patients with undiagnosed, suspected genetic conditions, a ... a higher molecular diagnostic yield than traditional molecular diagnostic ... . The study is being released to coincide with ... Exome sequencing, which sequences the protein­coding region of the ... present in a cell or organism), has been rapidly ...
(Date:10/17/2014)... for the first time how bacteria can grow directly ... the opportunity to get tremendous insights into bacteria behavior ... discovered the bacterial growth in chronic lung infections among ... by the immune cells. The researchers discovered the immune ... bacteria, forcing the bacteria to switch to a much ...
Breaking Biology News(10 mins):Improved electricity access has little impact on climate change 2Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2
... is available in German . , Four ... year,s Heinz Maier-Leibnitz Prize, Germany,s top research award for young ... the prize, which has been awarded annually by the Deutsche ... of Education and Research since 1977, that the majority of ...
... is available in German . The gene ... by cell division. It causes the production of a protein ... to 15 % of all human genes. When this gene ... is inhibited. Thereby the gene plays a decisive role in ...
... is a familiar phenomenon, even if the phrase is not: ... it around the block. After jogging regularly for a few ... three. With regular exercise, the body adapts, becoming fitter and ... oxygen to the muscles. The muscles get stronger, and so ...
Cached Biology News:Heinz Maier-Leibnitz Prizes 2009: Six young researchers recognized for outstanding achievements 2Heinz Maier-Leibnitz Prizes 2009: Six young researchers recognized for outstanding achievements 3Heinz Maier-Leibnitz Prizes 2009: Six young researchers recognized for outstanding achievements 4Heinz Maier-Leibnitz Prizes 2009: Six young researchers recognized for outstanding achievements 5Symposium to look at genetic basis of exercise 2Symposium to look at genetic basis of exercise 3
Human/Rat Neurogenin-2 MAb (Clone 7G4) Protein Family: Neural Crest Cell Markers, Transcription Factors...
Rat CINC-2 alpha/beta Affinity Purified Polyclonal Ab...
Monkey IL-2 ELISPOT Kit with white/opague microtiter plates...
Mouse TREM-2 Affinity Purified Polyclonal Ab...
Biology Products: